CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
GB1458148A
(en)
|
1974-04-19 |
1976-12-08 |
Wyeth John & Brother Ltd |
Carbocyclic-fused ring quinoline derivatives
|
JPS57123267A
(en)
|
1981-01-23 |
1982-07-31 |
Kansai Paint Co Ltd |
Thermosetting paint composition
|
US4526988A
(en)
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
DE3587022T2
(de)
|
1984-02-17 |
1993-06-17 |
Genentech Inc |
Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
|
US4582789A
(en)
|
1984-03-21 |
1986-04-15 |
Cetus Corporation |
Process for labeling nucleic acids using psoralen derivatives
|
DE8411409U1
(de)
|
1984-04-11 |
1984-08-30 |
Dr.-Ing. Walter Frohn-Betriebe, 8000 München |
Entgasungsventil fuer lager- und/oder transportbehaelter
|
US4563417A
(en)
|
1984-08-31 |
1986-01-07 |
Miles Laboratories, Inc. |
Nucleic acid hybridization assay employing antibodies to intercalation complexes
|
ATE37196T1
(de)
|
1984-11-22 |
1988-09-15 |
Holsten Brauerei Ag |
Bier und verfahren zu dessen herstellung.
|
EP0184365B1
(en)
|
1984-12-04 |
1993-08-04 |
Eli Lilly And Company |
Improvements in the treatment of tumors in mammals
|
JPS61148115A
(ja)
|
1984-12-21 |
1986-07-05 |
Tooa Eiyoo Kk |
難溶性薬物の徐放性製剤及びその製造法
|
JPS62168137A
(ja)
|
1985-12-20 |
1987-07-24 |
Fuji Photo Film Co Ltd |
ハロゲン化銀カラ−写真感光材料およびその処理方法
|
CH656535A5
(en)
|
1986-01-24 |
1986-07-15 |
Spirig Ag |
Process for the production of stable pharmaceutical tablets which disintegrate rapidly in water
|
JPH07106295B2
(ja)
|
1986-07-22 |
1995-11-15 |
エーザイ株式会社 |
調湿剤
|
US4743450A
(en)
|
1987-02-24 |
1988-05-10 |
Warner-Lambert Company |
Stabilized compositions
|
CA1339136C
(en)
|
1987-07-01 |
1997-07-29 |
Sailesh Amilal Varia |
Amorphous form of aztreonam
|
US5009894A
(en)
|
1988-03-07 |
1991-04-23 |
Baker Cummins Pharmaceuticals, Inc. |
Arrangement for and method of administering a pharmaceutical preparation
|
AU4128089A
(en)
|
1988-09-15 |
1990-03-22 |
Rorer International (Overseas) Inc. |
Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
US4983615A
(en)
|
1989-06-28 |
1991-01-08 |
Hoechst-Roussel Pharmaceuticals Inc. |
Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders
|
EP0408496A3
(en)
|
1989-07-12 |
1992-07-01 |
Ciba-Geigy Ag |
Solid dosage form for pharmaceutical substances
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
US5180818A
(en)
|
1990-03-21 |
1993-01-19 |
The University Of Colorado Foundation, Inc. |
Site specific cleavage of single-stranded dna
|
US5210015A
(en)
|
1990-08-06 |
1993-05-11 |
Hoffman-La Roche Inc. |
Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
|
DE69132843T2
(de)
|
1990-12-06 |
2002-09-12 |
Affymetrix Inc N D Ges D Staat |
Identifizierung von Nukleinsäuren in Proben
|
GB9105677D0
(en)
|
1991-03-19 |
1991-05-01 |
Ici Plc |
Heterocyclic compounds
|
US5367057A
(en)
|
1991-04-02 |
1994-11-22 |
The Trustees Of Princeton University |
Tyrosine kinase receptor flk-2 and fragments thereof
|
ES2108120T3
(es)
|
1991-05-10 |
1997-12-16 |
Rhone Poulenc Rorer Int |
Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
|
US5721237A
(en)
|
1991-05-10 |
1998-02-24 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
|
US5710158A
(en)
|
1991-05-10 |
1998-01-20 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
JPH04341454A
(ja)
|
1991-05-16 |
1992-11-27 |
Canon Inc |
シート収納装置
|
US5750376A
(en)
|
1991-07-08 |
1998-05-12 |
Neurospheres Holdings Ltd. |
In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
|
US5211951A
(en)
|
1991-07-24 |
1993-05-18 |
Merck & Co., Inc. |
Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
|
JPH05194259A
(ja)
*
|
1991-08-30 |
1993-08-03 |
Mitsubishi Kasei Corp |
抗消化性潰瘍剤
|
US5200194A
(en)
|
1991-12-18 |
1993-04-06 |
Alza Corporation |
Oral osmotic device
|
JPH08501203A
(ja)
|
1992-06-03 |
1996-02-13 |
ケイス・ウエスタン・リザーブ・ユニバーシティー |
生理活性物質を連続的に適用するための包帯
|
TW271400B
(lt)
*
|
1992-07-30 |
1996-03-01 |
Pfizer |
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
JPH06153952A
(ja)
|
1992-11-26 |
1994-06-03 |
Nobuaki Tamamaki |
微量未知二重鎖dna分子の増幅、標識を行うための前処理方法
|
GB9323290D0
(en)
|
1992-12-10 |
1994-01-05 |
Zeneca Ltd |
Quinazoline derivatives
|
CA2150372C
(en)
|
1993-01-19 |
2002-08-20 |
Nancy L. Mills |
Stable oral ci-981 formulation and process of preparing same
|
US6027880A
(en)
|
1995-08-02 |
2000-02-22 |
Affymetrix, Inc. |
Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
|
US6156501A
(en)
|
1993-10-26 |
2000-12-05 |
Affymetrix, Inc. |
Arrays of modified nucleic acid probes and methods of use
|
JPH07176103A
(ja)
|
1993-12-20 |
1995-07-14 |
Canon Inc |
光磁気記録再生システムならびにこれに用いる磁気ヘッド及び光磁気記録媒体
|
GB9326136D0
(en)
|
1993-12-22 |
1994-02-23 |
Erba Carlo Spa |
Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
US6811779B2
(en)
|
1994-02-10 |
2004-11-02 |
Imclone Systems Incorporated |
Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
|
JP3660391B2
(ja)
|
1994-05-27 |
2005-06-15 |
株式会社東芝 |
半導体装置の製造方法
|
JPH0848078A
(ja)
|
1994-08-05 |
1996-02-20 |
Nippon Paper Ind Co Ltd |
感熱記録体
|
GB9510757D0
(en)
|
1994-09-19 |
1995-07-19 |
Wellcome Found |
Therapeuticaly active compounds
|
US5656454A
(en)
|
1994-10-04 |
1997-08-12 |
President And Fellows Of Harvard College |
Endothelial cell-specific enhancer
|
JP3207058B2
(ja)
|
1994-11-07 |
2001-09-10 |
財団法人国際超電導産業技術研究センター |
超電導体薄膜及びその製造方法
|
IL115256A0
(en)
|
1994-11-14 |
1995-12-31 |
Warner Lambert Co |
6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
|
JPH08176138A
(ja)
|
1994-12-19 |
1996-07-09 |
Mercian Corp |
イソクマリン誘導体
|
US5948438A
(en)
|
1995-01-09 |
1999-09-07 |
Edward Mendell Co., Inc. |
Pharmaceutical formulations having improved disintegration and/or absorptivity
|
US5658374A
(en)
|
1995-02-28 |
1997-08-19 |
Buckman Laboratories International, Inc. |
Aqueous lecithin-based release aids and methods of using the same
|
US5624937A
(en)
|
1995-03-02 |
1997-04-29 |
Eli Lilly And Company |
Chemical compounds as inhibitors of amyloid beta protein production
|
US6579314B1
(en)
|
1995-03-10 |
2003-06-17 |
C.R. Bard, Inc. |
Covered stent with encapsulated ends
|
WO1996030347A1
(en)
|
1995-03-30 |
1996-10-03 |
Pfizer Inc. |
Quinazoline derivatives
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
DK0831829T3
(da)
|
1995-06-07 |
2003-12-15 |
Pfizer |
Heterocykliske, ringkondenserede pyrimidinderivater
|
US5654005A
(en)
|
1995-06-07 |
1997-08-05 |
Andrx Pharmaceuticals, Inc. |
Controlled release formulation having a preformed passageway
|
JPH0923885A
(ja)
|
1995-07-12 |
1997-01-28 |
Dai Ichi Seiyaku Co Ltd |
遺伝子発現ライブラリー及びその製造法
|
GB9514265D0
(en)
|
1995-07-13 |
1995-09-13 |
Wellcome Found |
Hetrocyclic compounds
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
GB9520822D0
(en)
|
1995-10-11 |
1995-12-13 |
Wellcome Found |
Therapeutically active compounds
|
US6346398B1
(en)
|
1995-10-26 |
2002-02-12 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
|
AU7340096A
(en)
|
1995-11-07 |
1997-05-29 |
Kirin Beer Kabushiki Kaisha |
Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
|
US5849759A
(en)
|
1995-12-08 |
1998-12-15 |
Berlex Laboratories, Inc. |
Naphthyl-substituted benzimidazole derivatives as anti-coagulants
|
GB9604361D0
(en)
|
1996-02-29 |
1996-05-01 |
Pharmacia Spa |
4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
|
JPH09234074A
(ja)
|
1996-03-04 |
1997-09-09 |
Sumitomo Electric Ind Ltd |
アダプター二本鎖dna及びそれを用いたdna増幅方法
|
DE69729583T2
(de)
|
1996-04-17 |
2005-06-09 |
Bristol-Myers Squibb Pharma Co. |
N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren
|
WO1997046313A1
(en)
|
1996-06-07 |
1997-12-11 |
Eos Biotechnology, Inc. |
Immobilised linear oligonucleotide arrays
|
CA2258093A1
(en)
|
1996-06-28 |
1998-01-08 |
Mark E. Duggan |
Fibrinogen receptor antagonists
|
DE69716916T2
(de)
|
1996-07-13 |
2003-07-03 |
Glaxo Group Ltd |
Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
ID19430A
(id)
|
1996-07-13 |
1998-07-09 |
Glaxo Group Ltd |
Senyawa senyawa heterosiklik
|
JPH10147524A
(ja)
|
1996-09-20 |
1998-06-02 |
Nippon Kayaku Co Ltd |
フォルスコリン誘導体含有経口製剤及び医薬製剤の製法
|
CN1252054C
(zh)
|
1996-09-25 |
2006-04-19 |
曾尼卡有限公司 |
抑制生长因子的作用的喹啉衍生物
|
CN1072657C
(zh)
|
1996-09-30 |
2001-10-10 |
日本农药株式会社 |
1,2,3-噻二唑衍生物和其盐以及农业园艺病毒防治剂及其使用方法
|
JPH10114655A
(ja)
|
1996-10-09 |
1998-05-06 |
Kyowa Hakko Kogyo Co Ltd |
固形製剤
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
KR20000057228A
(ko)
|
1996-11-27 |
2000-09-15 |
디. 제이. 우드, 스피겔 알렌 제이 |
축합된 비사이클릭 피리미딘 유도체
|
TW486370B
(en)
|
1996-12-25 |
2002-05-11 |
Yamanouchi Pharma Co Ltd |
Rapidly disintegrable pharmaceutical composition
|
AU6248798A
(en)
|
1997-01-29 |
1998-08-18 |
Eli Lilly And Company |
Treatment for premenstrual dysphoric disorder
|
JP3040486U
(ja)
|
1997-02-13 |
1997-08-19 |
有限会社ザップ |
フィッシングジャケット
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
ES2277382T3
(es)
|
1997-02-19 |
2007-07-01 |
Berlex, Inc. |
Derivados n-heterociclicos como inhibidores de nos.
|
US6090556A
(en)
|
1997-04-07 |
2000-07-18 |
Japan Science & Technology Corporation |
Method for quantitatively determining the expression of a gene
|
WO1998050346A2
(en)
|
1997-04-18 |
1998-11-12 |
Smithkline Beecham Plc |
Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
|
JPH10316576A
(ja)
|
1997-05-13 |
1998-12-02 |
Nissui Pharm Co Ltd |
キトサン含有錠剤
|
ES2151467T3
(es)
|
1997-05-23 |
2005-03-01 |
Bayer Corporation |
Arilureas para el tratamiento de enfermedades inflamatorias o inmunomoduladoras.
|
PL188450B1
(pl)
|
1997-06-10 |
2005-02-28 |
Synthon Bv |
Pochodne 4-fenylopiperydyny, sposób wytwarzania pochodnych 4-fenylopiperydyny, zastosowanie pochodnej 4-fenylopiperydyny oraz środek farmaceutyczny
|
US6093742A
(en)
|
1997-06-27 |
2000-07-25 |
Vertex Pharmaceuticals, Inc. |
Inhibitors of p38
|
AU8283898A
(en)
|
1997-06-30 |
1999-01-25 |
University Of Maryland At Baltimore |
Heparin binding-epidermal growth factor in the diagnosis of interstitial cystitis
|
BE1011251A3
(fr)
|
1997-07-03 |
1999-06-01 |
Ucb Sa |
Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
|
CO4940418A1
(es)
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
|
JP3765918B2
(ja)
|
1997-11-10 |
2006-04-12 |
パイオニア株式会社 |
発光ディスプレイ及びその駆動方法
|
JP4194678B2
(ja)
|
1997-11-28 |
2008-12-10 |
キリンファーマ株式会社 |
キノリン誘導体およびそれを含む医薬組成物
|
ATE529109T1
(de)
|
1997-12-22 |
2011-11-15 |
Bayer Healthcare Llc |
Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
|
TR200002618T2
(tr)
|
1997-12-22 |
2001-04-20 |
Bayer Corporation |
Sübstitüe edilmiş heterosiklik üreler kullanılarak raf kinazın inhibe edilmesi
|
TR200100874T2
(tr)
|
1997-12-22 |
2001-06-21 |
Bayer Corporation |
Simetrik ve simetrik olmayan sübstitüe edilmiş difenil üreler kullanılarak raf kinazın inhibe edilmesi
|
DE69836563T2
(de)
|
1997-12-22 |
2007-05-16 |
Bayer Pharmaceuticals Corp., West Haven |
INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYL-SUBSTITUIERTEN HARNSTOFFEN
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
TR200002447T2
(tr)
|
1998-02-25 |
2000-11-21 |
Genetics Institute, Inc. |
Fosfolinaz enzimlerinin inhibitörleri
|
AU741992B2
(en)
|
1998-03-06 |
2001-12-13 |
Adare Pharmaceuticals S.R.L. |
Fast disintegrating tablets
|
DE19814257A1
(de)
|
1998-03-31 |
1999-10-07 |
Asta Medica Ag |
Brauseformulierungen
|
JPH11322596A
(ja)
|
1998-05-12 |
1999-11-24 |
Shionogi & Co Ltd |
白金錯体および環状リン酸エステルアミドを含有する抗癌剤
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
US8097648B2
(en)
|
1998-06-17 |
2012-01-17 |
Eisai R&D Management Co., Ltd. |
Methods and compositions for use in treating cancer
|
US6653341B1
(en)
|
1998-06-17 |
2003-11-25 |
Eisai Co., Ltd. |
Methods and compositions for use in treating cancer
|
PT1087960E
(pt)
|
1998-06-17 |
2011-06-17 |
Eisai R&D Man Co Ltd |
Análogos macrocíclicos e métodos de sua utilização e preparação
|
ID27504A
(id)
|
1998-10-01 |
2001-04-12 |
Novartis Ag |
Formulasi oral baru
|
BR9915487A
(pt)
|
1998-11-19 |
2001-07-31 |
Warner Lambert Co |
N-[4-(3-cloro-4-flúor-fenilamino) - 7 - (3-morfolin-4-il-propóxi)-quinazolin-6-il]-acrilamida, um inibidor irreversìvel de tirosina quinases
|
WO2000042012A1
(en)
|
1999-01-13 |
2000-07-20 |
Bayer Corporation |
φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
|
UA73492C2
(en)
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
ES2208261T3
(es)
|
1999-01-22 |
2004-06-16 |
Kirin Beer Kabushiki Kaisha |
Derivados de quinolina y derivados de quinazolina.
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
DK1154774T3
(da)
|
1999-02-10 |
2005-09-26 |
Astrazeneca Ab |
Quinazolinderivater som angiogenesisinhibitorer
|
GB9904103D0
(en)
|
1999-02-24 |
1999-04-14 |
Zeneca Ltd |
Quinoline derivatives
|
JP2000328080A
(ja)
|
1999-03-12 |
2000-11-28 |
Shin Etsu Chem Co Ltd |
シートベルト用低摩擦化処理剤
|
YU13200A
(sh)
|
1999-03-31 |
2002-10-18 |
Pfizer Products Inc. |
Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
|
US6342221B1
(en)
|
1999-04-28 |
2002-01-29 |
Board Of Regents, The University Of Texas System |
Antibody conjugate compositions for selectively inhibiting VEGF
|
AU4778500A
(en)
|
1999-05-20 |
2000-12-12 |
Takeda Chemical Industries Ltd. |
Composition containing ascorbic acid salt
|
JP4304357B2
(ja)
|
1999-05-24 |
2009-07-29 |
独立行政法人理化学研究所 |
完全長cDNAライブラリーの作成法
|
PE20010306A1
(es)
|
1999-07-02 |
2001-03-29 |
Agouron Pharma |
Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
|
JP2001047890A
(ja)
|
1999-08-06 |
2001-02-20 |
Toyota Motor Corp |
車両用パワープラントの制御装置
|
AU6762400A
(en)
|
1999-08-12 |
2001-03-13 |
Cor Therapeutics, Inc. |
Inhibitors of factor xa
|
DOP2000000070A
(es)
|
1999-09-28 |
2002-02-28 |
Bayer Healthcare Llc |
Piridinas y piridacinas sustituidas con actividad de inhibición de angiogénesis
|
UA75054C2
(uk)
|
1999-10-13 |
2006-03-15 |
Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг |
Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
|
US6762180B1
(en)
|
1999-10-13 |
2004-07-13 |
Boehringer Ingelheim Pharma Kg |
Substituted indolines which inhibit receptor tyrosine kinases
|
JP2001131071A
(ja)
|
1999-10-29 |
2001-05-15 |
Meiji Seika Kaisha Ltd |
非晶質および非晶質を含有する医薬組成物
|
US20080241835A1
(en)
|
1999-11-01 |
2008-10-02 |
Genentech, Inc. |
Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
|
JP2003525595A
(ja)
|
1999-11-01 |
2003-09-02 |
キュラゲン コーポレイション |
脈管形成に含まれる差動発現遺伝子、それにコードされるポリペプチド、及びそれを用いた方法
|
AU1617901A
(en)
|
1999-11-16 |
2001-05-30 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Urea derivatives as anti-inflammatory agents
|
UA75055C2
(uk)
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
US20020010203A1
(en)
|
1999-12-22 |
2002-01-24 |
Ken Lipson |
Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
|
TWI281915B
(en)
|
1999-12-24 |
2007-06-01 |
Kirin Brewery |
Quinoline and quinazoline derivatives and drugs containing the same
|
AU2223501A
(en)
|
1999-12-24 |
2001-07-09 |
Kyowa Hakko Kogyo Co. Ltd. |
Fused purine derivatives
|
PT1255752E
(pt)
|
2000-02-15 |
2007-10-17 |
Pharmacia & Upjohn Co Llc |
Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo
|
JP3657203B2
(ja)
|
2000-04-21 |
2005-06-08 |
エーザイ株式会社 |
銅クロロフィリン塩含有液剤組成物
|
CN1116047C
(zh)
|
2000-06-05 |
2003-07-30 |
华中科技大学 |
用泥鳅制成的护肝功能食品及其制备方法
|
US20020040127A1
(en)
|
2000-06-09 |
2002-04-04 |
Yuqiu Jiang |
Compositions and methods for the therapy and diagnosis of colon cancer
|
AU2001277621A1
(en)
|
2000-08-09 |
2002-03-04 |
Astrazeneca Ab |
Antiangiogenic bicyclic derivatives
|
ATE355275T1
(de)
|
2000-10-20 |
2006-03-15 |
Eisai R&D Man Co Ltd |
Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
|
TWI283575B
(en)
|
2000-10-31 |
2007-07-11 |
Eisai Co Ltd |
Medicinal compositions for concomitant use as anticancer agent
|
PT1339458E
(pt)
|
2000-11-22 |
2007-11-09 |
Novartis Ag |
Combinação compreendendo um agente para diminuir a actividade do vegf e um agente para diminuir a actividade do egf
|
WO2002044156A2
(en)
|
2000-11-29 |
2002-06-06 |
Glaxo Group Limited |
Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
|
US6544552B2
(en)
|
2001-01-11 |
2003-04-08 |
Particle And Coating Technologies, Inc. |
Method of producing porous tablets with improved dissolution properties
|
CN100523216C
(zh)
|
2001-03-02 |
2009-08-05 |
匹兹堡大学 |
Pcr方法
|
US6960580B2
(en)
|
2001-03-08 |
2005-11-01 |
Millennium Pharmaceuticals, Inc. |
Nitrogenous heterocyclic substituted quinoline compounds
|
CA2442849A1
(en)
|
2001-04-06 |
2002-10-17 |
Wyeth |
Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
|
US20040171068A1
(en)
|
2001-04-19 |
2004-09-02 |
Juergen Wehland |
Method for producing stable, regeneratable antibody arrays
|
EP1382604B1
(en)
|
2001-04-27 |
2005-12-28 |
Kirin Beer Kabushiki Kaisha |
Quinoline derivative having azolyl group and quinazoline derivative
|
JP3602513B2
(ja)
|
2001-04-27 |
2004-12-15 |
麒麟麦酒株式会社 |
アゾリル基を有するキノリン誘導体およびキナゾリン誘導体
|
JP2003026576A
(ja)
|
2001-05-09 |
2003-01-29 |
Eisai Co Ltd |
味覚改善製剤
|
US6812341B1
(en)
|
2001-05-11 |
2004-11-02 |
Ambion, Inc. |
High efficiency mRNA isolation methods and compositions
|
PT1392313E
(pt)
|
2001-05-16 |
2007-07-17 |
Novartis Ag |
Combinação que compreende n - ( 5- [ 4- ( metil-piperazinomrtil ) - benxoilamido ] - 2 -metilfenil ) - 4 -( 3 - piridil ) - 2 - pirimidina-amina e um agente quimioterapêutico
|
PE20030062A1
(es)
|
2001-05-30 |
2003-02-08 |
Sugen Inc |
Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
|
DE60233736D1
(de)
|
2001-06-22 |
2009-10-29 |
Kirin Pharma K K |
Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus-proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung
|
US20030013208A1
(en)
|
2001-07-13 |
2003-01-16 |
Milagen, Inc. |
Information enhanced antibody arrays
|
GB0117144D0
(en)
|
2001-07-13 |
2001-09-05 |
Glaxo Group Ltd |
Process
|
JP4827154B2
(ja)
|
2001-07-25 |
2011-11-30 |
株式会社オーイズミ |
遊技装置
|
JP3088018U
(ja)
|
2001-08-02 |
2002-08-30 |
ユーエス工業株式会社 |
垂木支持用ブラケットを備えたパイプバンド
|
GB0119467D0
(en)
|
2001-08-09 |
2001-10-03 |
Smithkline Beecham Plc |
Novel compound
|
US7063946B2
(en)
|
2001-09-10 |
2006-06-20 |
Meso Scale Technologies, Llc. |
Methods, reagents, kits and apparatus for protein function analysis
|
JP2005511506A
(ja)
|
2001-09-20 |
2005-04-28 |
アブ サイエンス |
間質性膀胱炎を治療するための強力で選択的かつ非毒性のc−kit阻害剤の使用方法
|
US6765012B2
(en)
|
2001-09-27 |
2004-07-20 |
Allergan, Inc. |
3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
|
JP4130179B2
(ja)
|
2001-09-27 |
2008-08-06 |
ノバルティス アクチエンゲゼルシャフト |
骨髄腫を処置するためのc−kit阻害剤の使用
|
WO2003030908A2
(en)
|
2001-10-09 |
2003-04-17 |
The University Of Cincinnati |
Inhibitors of the egf receptor for the treatment of thyroid cancer
|
US7658924B2
(en)
|
2001-10-11 |
2010-02-09 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
EP1447405A4
(en)
|
2001-10-17 |
2005-01-12 |
Kirin Brewery |
QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS
|
PL370137A1
(en)
|
2001-11-27 |
2005-05-16 |
Wyeth Holdings Corporation |
3-cyanoquinolines as inhibitors of egf-r and her2 kinases
|
GB0201508D0
(en)
|
2002-01-23 |
2002-03-13 |
Novartis Ag |
Organic compounds
|
JP2003252737A
(ja)
|
2002-03-04 |
2003-09-10 |
Shin Etsu Chem Co Ltd |
口腔用組成物
|
CA2478169C
(en)
|
2002-03-04 |
2013-04-16 |
Imclone Systems Incorporated |
Human antibodies specific to kdr and uses thereof
|
AU2003211594A1
(en)
|
2002-03-05 |
2003-09-16 |
Eisai Co., Ltd. |
Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor
|
JP4619658B2
(ja)
|
2002-03-12 |
2011-01-26 |
富山化学工業株式会社 |
快い味の経口懸濁液および方法
|
US20050233991A1
(en)
|
2002-03-20 |
2005-10-20 |
Ravi Salgia |
Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
|
US6790852B2
(en)
|
2002-04-18 |
2004-09-14 |
Hoffmann-La Roche Inc. |
2-(2,6-dichlorophenyl)-diarylimidazoles
|
US7598258B2
(en)
|
2002-05-01 |
2009-10-06 |
Kirin Beer Kabushiki Kaisha |
Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
|
TW200406374A
(en)
|
2002-05-29 |
2004-05-01 |
Novartis Ag |
Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
WO2004006862A2
(en)
|
2002-07-16 |
2004-01-22 |
Children's Medical Center Corporation |
A method for the modulation of angiogenesis
|
JP2005533893A
(ja)
|
2002-07-22 |
2005-11-10 |
アスペン・エアロジェルズ・インコーポレーテッド |
ポリイミドエーロゲル、炭素エーロゲル、及び金属炭化物エーロゲル並びにこれらの製造方法。
|
US7169936B2
(en)
|
2002-07-23 |
2007-01-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
|
US7252976B2
(en)
|
2002-08-28 |
2007-08-07 |
Board Of Regents The University Of Texas System |
Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample
|
JP4183193B2
(ja)
|
2002-08-30 |
2008-11-19 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
含窒素芳香環誘導体
|
GB0223380D0
(en)
|
2002-10-09 |
2002-11-13 |
Astrazeneca Ab |
Combination therapy
|
JP2006504745A
(ja)
|
2002-10-09 |
2006-02-09 |
コーザン バイオサイエンシス インコーポレイテッド |
エポd及び5−fu/ゲムシタビン
|
JP4749660B2
(ja)
|
2002-10-16 |
2011-08-17 |
武田薬品工業株式会社 |
安定な固形製剤
|
CA2502219C
(en)
|
2002-10-16 |
2012-05-29 |
Takeda Pharmaceutical Company Limited |
A process for producing an amorphous isomer of lansoprazole
|
ATE327977T1
(de)
|
2002-10-21 |
2006-06-15 |
Warner Lambert Co |
Tetrahydrochinolin-derivate als crth2 antagonisten
|
EP1566379A4
(en)
|
2002-10-29 |
2005-11-09 |
Kirin Brewery |
QUINOLINE AND QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FLT3 AND MEDICAL COMPOSITIONS CONTAINING SAME
|
DE10250711A1
(de)
|
2002-10-31 |
2004-05-19 |
Degussa Ag |
Pharmazeutische und kosmetische Zubereitungen
|
CA2502979A1
(en)
|
2002-11-06 |
2004-05-21 |
Cyclacel Limited |
Pharmaceutical composition comprising a cdk inhibitor and gemcitabine
|
GB0226434D0
(en)
|
2002-11-13 |
2002-12-18 |
Astrazeneca Ab |
Combination product
|
ITSV20020056A1
(it)
|
2002-11-14 |
2004-05-15 |
Alstom Transp Spa |
Dispositivo e metodo di verifica di motori software logici di comando di impianti ferroviari, in particolare di impianti di stazione
|
AR042042A1
(es)
|
2002-11-15 |
2005-06-08 |
Sugen Inc |
Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
|
US7399866B2
(en)
|
2003-01-14 |
2008-07-15 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
JP3581361B1
(ja)
|
2003-02-17 |
2004-10-27 |
株式会社脳機能研究所 |
脳活動測定装置
|
AU2004212976A1
(en)
|
2003-02-19 |
2004-09-02 |
Biovail Laboratories Inc. |
Rapid absorption selective 5-HT agonist formulations
|
DK1603570T5
(da)
|
2003-02-26 |
2013-12-09 |
Sugen Inc |
Aminoheteroarylforbindelser som proteinkinaseinhibitorer
|
ZA200507321B
(en)
|
2003-03-05 |
2007-03-28 |
Celgene Corp |
Diphenylethylene compounds and uses thereof
|
EP1604665B1
(en)
|
2003-03-10 |
2011-05-11 |
Eisai R&D Management Co., Ltd. |
C-kit kinase inhibitor
|
MXPA05009751A
(es)
|
2003-03-14 |
2005-10-26 |
Taisho Pharmaceutical Co Ltd |
Anticuerpo monoclonal e hibridoma que lo produce.
|
EP1604981A4
(en)
|
2003-03-14 |
2008-12-24 |
Ono Pharmaceutical Co |
NITROGENIC HETEROCYCLIC DERIVATIVES AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE SUBSTANCE
|
EP1608333A1
(en)
*
|
2003-04-02 |
2005-12-28 |
Pliva Istrazivanje i Razvoj d.o.o. |
Pharmaceutical compositions having reduced bitter taste
|
US20050014753A1
(en)
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
US20070117842A1
(en)
|
2003-04-22 |
2007-05-24 |
Itaru Arimoto |
Polymorph of 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6- quinolinecarboxamide and a process for the preparation of the same
|
EP1473043A1
(en)
|
2003-04-29 |
2004-11-03 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Pharmaceutical combination for the treatment of diseases involving cell proliferation, migration or apotosis of myeloma cells, or angiogenesis
|
US7107104B2
(en)
|
2003-05-30 |
2006-09-12 |
Medtronic, Inc. |
Implantable cortical neural lead and method
|
JP2005008534A
(ja)
|
2003-06-17 |
2005-01-13 |
Soc De Conseils De Recherches & D'applications Scientifiques (Scras) |
抗癌剤及び癌の治療方法
|
KR20120093411A
(ko)
|
2003-07-10 |
2012-08-22 |
아스트라제네카 아베 |
백금 화합물 및 임의적으로 이온화 방사능과 조합된 퀴나졸린 유도체 zd6474의 혈관신생 및/또는 증가된 혈관 투과성 관련 질환 치료 용도
|
CA2535242A1
(en)
|
2003-08-15 |
2005-02-24 |
Ab Science |
Use of c-kit inhibitors for treating type ii diabetes
|
US7485658B2
(en)
|
2003-08-21 |
2009-02-03 |
Osi Pharmaceuticals, Inc. |
N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors
|
AP2006003553A0
(en)
|
2003-08-21 |
2006-04-30 |
Osi Pharm Inc |
N-substituted pyrazolyl-amidyl-benzimidazolyl C- kit inhibitors.
|
AP2006003549A0
(en)
|
2003-08-21 |
2006-04-30 |
Osi Pharm Inc |
N-substituted benzimidazolyl C-kit inhibitors.
|
US7312243B1
(en)
|
2003-08-29 |
2007-12-25 |
Jay Pravda |
Materials and methods for treatment of gastrointestinal disorders
|
CA2537991A1
(en)
|
2003-09-23 |
2005-03-31 |
Novartis Ag |
Combination of a vegf receptor inhibitor with a chemotherapeutic agent
|
ATE517091T1
(de)
|
2003-09-26 |
2011-08-15 |
Exelixis Inc |
C-met-modulatoren und verwendungsverfahren
|
KR200340552Y1
(ko)
|
2003-10-08 |
2004-02-11 |
주식회사 엘지화학 |
창틀 내부에 블라인드 및 방범창 설치가 용이한 이중창틀
|
JP2005124034A
(ja)
|
2003-10-20 |
2005-05-12 |
Nippon Telegr & Teleph Corp <Ntt> |
発信者の特定及び発信者への呼び返しを可能とする回線設定方法
|
WO2005044788A1
(ja)
|
2003-11-11 |
2005-05-19 |
Eisai Co., Ltd. |
ウレア誘導体およびその製造方法
|
TW200529849A
(en)
|
2003-11-28 |
2005-09-16 |
Novartis Ag |
Diaryl urea derivatives in the treatment of protein kinase dependent diseases
|
US6984403B2
(en)
|
2003-12-04 |
2006-01-10 |
Pfizer Inc. |
Azithromycin dosage forms with reduced side effects
|
CN1946417A
(zh)
|
2003-12-05 |
2007-04-11 |
阿德内克休斯治疗公司 |
2型血管内皮生长因子受体的抑制剂
|
PL1698623T3
(pl)
*
|
2003-12-25 |
2015-08-31 |
Eisai R&D Man Co Ltd |
Postać krystaliczna soli 4-(3-chloro-4-(cyklopropyloaminokarbonylo)aminofenoksy)-7-metoksy-6-chinolinokarboksamidu lub jej solwatu i sposoby ich wytwarzania
|
US7435823B2
(en)
|
2004-01-23 |
2008-10-14 |
Amgen Inc. |
Compounds and methods of use
|
JP4457108B2
(ja)
|
2004-02-27 |
2010-04-28 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
新規ピリジン誘導体およびピリミジン誘導体(1)
|
KR20050091462A
(ko)
|
2004-03-12 |
2005-09-15 |
한국과학기술연구원 |
푸로피리미딘 화합물 및 이를 포함하는 ddr2 티로신키나아제 활성 저해제
|
US7459562B2
(en)
|
2004-04-23 |
2008-12-02 |
Bristol-Myers Squibb Company |
Monocyclic heterocycles as kinase inhibitors
|
AU2005245492A1
(en)
|
2004-05-21 |
2005-12-01 |
Novartis Vaccines And Diagnostics, Inc. |
Substituted quinoline derivatives as mitotic kinesin inhibitors
|
RU2006146619A
(ru)
|
2004-06-03 |
2008-07-20 |
Ф.Хоффманн-Ля Рош Аг (Ch) |
Лечение гемцитабином и ингибитором рецептора эпидермального фактора роста(egfr)
|
AU2005265027A1
(en)
*
|
2004-06-18 |
2006-01-26 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
|
US7173031B2
(en)
|
2004-06-28 |
2007-02-06 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
US20050288521A1
(en)
|
2004-06-29 |
2005-12-29 |
Phytogen Life Sciences Inc. |
Semi-synthetic conversion of paclitaxel to docetaxel
|
JP5368701B2
(ja)
|
2004-07-02 |
2013-12-18 |
エクセリクシス、インコーポレイテッド |
c−Metモジュレーター及び使用方法
|
US8772269B2
(en)
|
2004-09-13 |
2014-07-08 |
Eisai R&D Management Co., Ltd. |
Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
|
EP2364699A1
(en)
|
2004-09-13 |
2011-09-14 |
Eisai R&D Management Co., Ltd. |
Joint use of sulfonamide based compound with angiogenesis inhibitor
|
US7306807B2
(en)
|
2004-09-13 |
2007-12-11 |
Wyeth |
Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease
|
AU2005283422C1
(en)
*
|
2004-09-17 |
2017-02-02 |
Eisai R & D Management Co., Ltd. |
Medicinal composition
|
WO2006036941A2
(en)
|
2004-09-27 |
2006-04-06 |
Kosan Biosciences Incorporated |
Specific kinase inhibitors
|
KR20070057901A
(ko)
|
2004-10-01 |
2007-06-07 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미립자 함유 조성물 및 그의 제조 방법
|
CN101495513B
(zh)
|
2004-10-19 |
2014-08-06 |
安姆根有限公司 |
促血管生成素-2特异性结合剂
|
EP1827445A2
(en)
|
2004-11-22 |
2007-09-05 |
King Pharmaceuticals Research and Development Inc. |
Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
|
BRPI0517396A
(pt)
|
2004-11-23 |
2008-10-14 |
Dong Wha Pharm Ind Co Ltd |
preparação oral com melhor biodisponibilidade
|
MX2007006230A
(es)
|
2004-11-30 |
2007-07-25 |
Amgen Inc |
Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
|
CN100341504C
(zh)
|
2004-12-01 |
2007-10-10 |
鲁南制药集团股份有限公司 |
佐米曲普坦速释制剂
|
EP1824843A2
(en)
|
2004-12-07 |
2007-08-29 |
Locus Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
NZ556029A
(en)
|
2004-12-21 |
2010-04-30 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
JP2006230816A
(ja)
|
2005-02-25 |
2006-09-07 |
H & A Investment:Kk |
サンダル用ホルダー
|
US20080286282A1
(en)
|
2005-02-28 |
2008-11-20 |
Eisai R & D Management Co., Ltd. |
Novel Use of Sulfonamide Compound in Combination with Angiogenesis Inhibitor
|
WO2006090931A1
(ja)
|
2005-02-28 |
2006-08-31 |
Eisai R & D Management Co., Ltd. |
スルホンアミド化合物の抗癌剤との新規併用
|
EP1859793B1
(en)
|
2005-02-28 |
2011-04-20 |
Eisai R&D Management Co., Ltd. |
Novel combinational use of a sulfonamide compound in the treatment of cancer
|
AU2006244885B2
(en)
|
2005-05-09 |
2011-03-31 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
DE602006011150D1
(de)
|
2005-05-17 |
2010-01-28 |
Actelion Pharmaceuticals Ltd |
Dispergierbare bosertan-tablette
|
CA2608733A1
(en)
|
2005-05-17 |
2007-02-01 |
Plexxikon, Inc. |
Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
|
EP3088400A1
(en)
|
2005-06-22 |
2016-11-02 |
Plexxikon Inc. |
Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors
|
JP4733700B2
(ja)
|
2005-06-23 |
2011-07-27 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
4−(3−クロロ−4−(シクロプロピルアミノカルボニル)アミノフェノキシ)−7−メトキシ−6−キノリンカルボキサミドの塩のアモルファスおよびその製造方法
|
US7550483B2
(en)
|
2005-06-23 |
2009-06-23 |
Eisai R&D Management Co., Ltd. |
Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
|
EP1926494A2
(en)
|
2005-06-29 |
2008-06-04 |
Carlo Pedone |
Agonistic and antagonistic peptide mimetics of the vegf alpha-helix binding region for use in therapy
|
AU2006230974C1
(en)
|
2005-07-11 |
2012-02-02 |
Takeda Pharma A/S |
Benzimidazole formulation
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
US7820664B2
(en)
|
2007-01-19 |
2010-10-26 |
Bayer Schering Pharma Ag |
Inhibitors of MEK
|
WO2007014335A2
(en)
|
2005-07-27 |
2007-02-01 |
The University Of Texas System |
Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
|
EP1925941B1
(en)
|
2005-08-01 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
EP1925676A4
(en)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
|
ES2424651T3
(es)
|
2005-08-24 |
2013-10-07 |
Eisai R&D Management Co., Ltd. |
Nuevo derivado de piridina y derivado de pirimidina (3)
|
WO2007026864A1
(ja)
|
2005-09-01 |
2007-03-08 |
Eisai R & D Management Co., Ltd. |
崩壊性の改善された医薬組成物の製造方法
|
CN1308012C
(zh)
|
2005-11-02 |
2007-04-04 |
广州中医药大学第二附属医院 |
一种治疗脑出血的中药组合物及其制备方法
|
CA2627598C
(en)
|
2005-11-07 |
2013-06-25 |
Eisai R & D Management Co., Ltd. |
Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
|
EP1964837A4
(en)
|
2005-11-22 |
2010-12-22 |
Eisai R&D Man Co Ltd |
Antitumor agent against multiple myeloma
|
DK1959955T3
(da)
|
2005-12-05 |
2011-02-07 |
Pfizer Prod Inc |
Fremgangsmåde til behandling af abnorm cellevækst
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
KR100728926B1
(ko)
|
2006-03-20 |
2007-06-15 |
삼성전자주식회사 |
3축 힌지 구조를 갖는 휴대용 전자기기
|
CN101443009A
(zh)
|
2006-05-18 |
2009-05-27 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
WO2008023698A1
(fr)
|
2006-08-23 |
2008-02-28 |
Eisai R & D Management Co., Ltd. |
Sel de dérivé de phénoxypyridine ou son cristal et procédé de production
|
EP2065372B1
(en)
|
2006-08-28 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
US7790885B2
(en)
|
2006-08-31 |
2010-09-07 |
Eisai R&D Management Co., Ltd. |
Process for preparing phenoxypyridine derivatives
|
AU2007293280A1
(en)
|
2006-09-07 |
2008-03-13 |
Astrazeneca Ab |
Method for evaluating patients for treatment with drugs targeting RET receptor tyrosine kinase
|
BRPI0719276A2
(pt)
|
2006-10-12 |
2014-04-29 |
Ptc Therapeutics Inc |
Métodos para tratar, prevenir ou controlar uma doença associada com uma mutação sem sentido, para tratar, prevenir ou reduzir tosse, para aumentar expressão de distrofina em músculo de um paciente e para administrar um composto.
|
JP2009184925A
(ja)
*
|
2006-11-02 |
2009-08-20 |
Dai Ichi Seiyaku Co Ltd |
5−(1h−1,2,3−トリアゾール−4−イル)−1h−ピラゾール誘導体
|
WO2008088088A1
(ja)
|
2007-01-19 |
2008-07-24 |
Eisai R & D Management Co., Ltd. |
膵癌治療用組成物
|
WO2008093855A1
(ja)
|
2007-01-29 |
2008-08-07 |
Eisai R & D Management Co., Ltd. |
未分化型胃癌治療用組成物
|
JPWO2008102870A1
(ja)
|
2007-02-23 |
2010-05-27 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Hgfr遺伝子増幅細胞株に優れた細胞増殖阻害効果および抗腫瘍効果を示すピリジン誘導体またはピリミジン誘導体
|
US20100098690A1
(en)
|
2007-03-05 |
2010-04-22 |
Kyowa Hakko Kirin Co., Ltd. |
Pharmaceutical composition
|
US20100104567A1
(en)
|
2007-03-05 |
2010-04-29 |
Kyowa Hakko Kirin Co., Ltd. |
Pharmaceutical composition
|
GB2448181B
(en)
|
2007-04-05 |
2011-11-09 |
Ford Global Tech Llc |
Vehicle headlight beam controls
|
US7807172B2
(en)
|
2007-06-13 |
2010-10-05 |
University Of Washington |
Methods and compositions for detecting thyroglobulin in a biological sample
|
PE20090368A1
(es)
|
2007-06-19 |
2009-04-28 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf
|
CA2694646C
(en)
|
2007-07-30 |
2017-09-05 |
Ardea Biosciences, Inc. |
Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
|
CA2704000C
(en)
|
2007-11-09 |
2016-12-13 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
JP2009132660A
(ja)
|
2007-11-30 |
2009-06-18 |
Eisai R & D Management Co Ltd |
食道癌治療用組成物
|
CA2713930A1
(en)
|
2008-01-29 |
2009-08-06 |
Eisai R & D Management Co., Ltd. |
Combined use of angiogenesis inhibitor and taxane
|
GB2456907A
(en)
|
2008-01-30 |
2009-08-05 |
Astrazeneca Ab |
Method for determining subsequent VEGFR2 inhibitor therapy comprising measuring baseline VEGF level.
|
EP2259844A4
(en)
|
2008-03-05 |
2012-02-01 |
Vicus Therapeutics Llc |
COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES
|
US8044240B2
(en)
|
2008-03-06 |
2011-10-25 |
Ardea Biosciences Inc. |
Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
KR20110014149A
(ko)
|
2008-04-14 |
2011-02-10 |
아디아 바이오사이언스즈 인크. |
조성물 및 이것의 제조 및 사용 방법
|
WO2009137649A2
(en)
|
2008-05-07 |
2009-11-12 |
The Trustees Of The University Of Pennsylvania |
Methods for treating thyroid cancer
|
CA2723617A1
(en)
|
2008-05-14 |
2009-11-19 |
Amgen Inc. |
Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
|
WO2009150256A1
(en)
|
2008-06-13 |
2009-12-17 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Markers for predicting response and survival in anti-egfr treated patients
|
BRPI0915901A2
(pt)
|
2008-07-11 |
2015-10-27 |
Novartis Ag |
combinação de (a) um inibidor de fosfoinositídeo 3-quinase e (b) um modulador da via ras/raf/mek
|
EP2350663A2
(en)
|
2008-10-21 |
2011-08-03 |
Bayer HealthCare LLC |
Identification of signature genes associated with hepatocellular carcinoma
|
WO2010086964A1
(ja)
|
2009-01-28 |
2010-08-05 |
株式会社 静岡カフェイン工業所 |
がん治療のための併用療法
|
AU2010279359A1
(en)
|
2009-08-07 |
2012-02-16 |
The Wistar Institute |
Compositions containing JARID1B inhibitors and methods for treating cancer
|
HUE026957T2
(en)
*
|
2009-08-19 |
2016-07-28 |
Eisai R&D Man Co Ltd |
A pharmaceutical composition comprising a quinoline derivative
|
US20120207753A1
(en)
|
2009-08-21 |
2012-08-16 |
Centre Hospitalier Universitaire Vaudois |
Methods of using cd44 fusion proteins to treat cancer
|
EP2293071A1
(en)
|
2009-09-07 |
2011-03-09 |
Universität Zu Köln |
Biomarker for colorectal cancer
|
ES2573515T3
(es)
|
2010-06-25 |
2016-06-08 |
Eisai R&D Management Co., Ltd. |
Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
|
KR20130091331A
(ko)
|
2010-07-16 |
2013-08-16 |
교와 핫꼬 기린 가부시키가이샤 |
함질소 방향족 복소환 유도체
|
BR112013001431A2
(pt)
|
2010-07-19 |
2016-05-31 |
Hoffmann La Roche |
método de identificação de pacientes com maior probabilidade de reação a terapia anticâncer
|
KR20130126576A
(ko)
|
2010-07-19 |
2013-11-20 |
에프. 호프만-라 로슈 아게 |
항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
|
RU2013106938A
(ru)
|
2010-07-19 |
2014-08-27 |
Ф.Хоффманн-Ля Рош Аг |
Биомаркеры в плазме крови, предназначенные для комбинированных терапий с использованием бевацизумаба при лечении рака молочной железы
|
SG187012A1
(en)
|
2010-07-19 |
2013-02-28 |
Hoffmann La Roche |
Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
|
WO2012019300A1
(en)
|
2010-08-10 |
2012-02-16 |
Siu K W Michael |
Endometrial cancer biomarkers and methods of identifying and using same
|
US20120077837A1
(en)
|
2010-09-24 |
2012-03-29 |
Eisai R&D Management Co., Ltd. |
Anti-tumor agent
|
JP5707518B2
(ja)
|
2011-02-28 |
2015-04-30 |
カリトル サイエンシズ, エルエルシー |
置換型キノリン化合物及び使用方法
|
CA2864394C
(en)
|
2011-03-02 |
2021-10-19 |
Jack Roth |
A method of predicting a response to a tusc2 therapy
|
ES2699965T3
(es)
|
2011-03-10 |
2019-02-13 |
Provectus Pharmatech Inc |
Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer
|
RU2580609C2
(ru)
|
2011-04-18 |
2016-04-10 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое терапевтическое средство
|
WO2012154935A1
(en)
|
2011-05-12 |
2012-11-15 |
Eisai R&D Management Co., Ltd. |
Biomarkers that are predictive of responsiveness or non-responsiveness to treatment with lenvatinib or a pharmaceutically acceptable salt thereof
|
US20140148483A1
(en)
|
2011-05-17 |
2014-05-29 |
Eisai R&D Management Co., Ltd. |
Method For Predicting Effectiveness Of Angiogenesis Inhibitor
|
ES2841809T3
(es)
|
2011-06-03 |
2021-07-09 |
Eisai R&D Man Co Ltd |
Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
|
MY193562A
(en)
|
2011-08-01 |
2022-10-19 |
Genentech Inc |
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
US20130071403A1
(en)
|
2011-09-20 |
2013-03-21 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
SG11201407190TA
(en)
|
2012-05-15 |
2014-12-30 |
Bristol Myers Squibb Co |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
WO2013171287A1
(en)
|
2012-05-16 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
|
LT2904011T
(lt)
|
2012-10-02 |
2017-11-10 |
Bristol-Myers Squibb Company |
Anti-kir antikūnų ir anti-pd-1 antikūnų derinys, akirtas vėžio gydymui
|
MX2015007185A
(es)
|
2012-12-04 |
2017-09-05 |
Eisai R&D Man Co Ltd |
Uso de eribulina en el tratamiento de cancer de pecho.
|
EP2945652B1
(en)
|
2013-01-18 |
2021-07-07 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
RS57602B1
(sr)
|
2013-02-28 |
2018-11-30 |
Eisai R&D Man Co Ltd |
Derivat tetrahidroimidazo[1,5-d][1,4]oksazepina
|
US10517861B2
(en)
|
2013-05-14 |
2019-12-31 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
JP6404242B2
(ja)
|
2013-06-26 |
2018-10-10 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用
|
US9174998B2
(en)
|
2013-12-25 |
2015-11-03 |
Eisai R&D Management Co., Ltd. |
(6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
EP3102237B1
(en)
|
2014-02-04 |
2020-12-02 |
Incyte Corporation |
Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
|
HRP20221047T1
(hr)
|
2014-08-28 |
2022-11-11 |
Eisai R&D Management Co., Ltd. |
Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
CA2988707C
(en)
|
2015-06-16 |
2023-10-10 |
Eisai R&D Management Co., Ltd. |
Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
|
EP3315499B1
(en)
|
2015-06-23 |
2021-04-07 |
Eisai R&D Management Co., Ltd. |
Crystal of (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide
|
US20200375975A1
(en)
|
2016-04-15 |
2020-12-03 |
Eisai R&D Management Co., Ltd. |
Treatment of Renal Cell Carcinoma with Lenvatinib and Everolimus
|